Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the results of the ImPassion130, a phase III study that adds atezolizumab to 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple negative breast cancer (TNBC).
ImPasstion130 Trial in TNBC
